국가: 미국
언어: 영어
출처: NLM (National Library of Medicine)
theophylline, anhydrous (UNII: 0I55128JYK) (theophylline, anhydrous - UNII:0I55128JYK)
Actavis Mid Atlantic LLC
Theophylline, anhydrous
LIQUID
80 mg in 15 mL
ORAL
PRESCRIPTION DRUG
Theophylline is indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis. Theophylline Elixir is contraindicated in patients with a history of hypersensitivity to theophylline or other components in the product.
Theophylline Elixir, 80 mg/15 mL with 20% alcohol, is a fruit-flavored reddish-orange liquid available in one pint (473 mL) and one gallon (3785 mL) bottles. Store at controlled room temperature 15º-30ºC (59º-86ºF). Do not refrigerate. Dispense in a tight, light-resistant container as defined in the USP. CAUTION: Federal law prohibits dispensing without prescription. Manufactured by Barre-National Inc. Baltimore, MD 21244 an ALPHARMA USPD company Form No. 1444 Rev. 1/97 C1 VC1299
THEOPHYLLINE- THEOPHYLLINE, ANHYDROUS LIQUID ACTAVIS MID ATLANTIC LLC ---------- THEOPHYLLINE ELIXIR FORM NO. 1444 DESCRIPTION THEOPHYLLINE IS STRUCTURALLY CLASSIFIED AS A METHYLXANTHINE. IT OCCURS AS A WHITE, ODORLESS, CRYSTALLINE POWDER WITH A BITTER TASTE. ANHYDROUS THEOPHYLLINE HAS THE CHEMICAL NAME 1H-PURINE- 2,6-DIONE,3,7-DIHYDRO-1,3-DIMETHYL-, AND IS REPRESENTED BY THE FOLLOWING STRUCTURAL FORMULA: The molecular formula of anhydrous theophylline is C H N O with a molecular weight of 180.17. Theophylline Elixir is available as a liquid intended for oral administration, containing 80 mg of anhydrous theophylline and 20% alcohol per 15 mL (one tablespoonful). Also contains: FD&C Red #40, Artificial Mixed Fruit Flavor, Propylene Glycol, Purified Water, Saccharin Sodium. May contain Citric Acid to adjust pH. CLINICAL PHARMACOLOGY MECHANISM OF ACTION: Theophylline has two distinct actions in the airways of patients with reversible obstruction; smooth muscle relaxation (i.e., bronchodilation) and suppression of the response of the airways to stimuli (i.e., non-bronchodilator prophylactic effects). While the mechanisms of action of theophylline are not known with certainty, studies in animals suggest that bronchodilatation is mediated by the inhibition of two isozymes of phosphodiesterase (PDE III and, to a lesser extent, PDE IV) while non-bronchodilator prophylactic actions are probably mediated through one or more different molecular mechanisms, that do not involve inhibition of PDE III or antagonism of adenosine receptors. Some of the adverse effects associated with theophylline appear to be mediated by inhibition of PDE III (e.g., hypotension, tachycardia, headache, and emesis) and adenosine receptor antagonism (e.g., alterations in cerebral blood flow). Theophylline increases the force of contraction of diaphragmatic muscles. This action appears to be due to enhancement of calcium uptake through an adenosine-mediated channel. SERUM CONCENTRATION-EFFECT RELATIONSHIP: Bronchodilation occurs over the serum theop 전체 문서 읽기